Bod is launching a new soft gel CBD product in Australia next month under its MediCabilis brand.
Bod Bio-Absorb 100 is currently being used in the firm’s phase II clinical trial on symptoms associated with insomnia and will be available to patients via the special access scheme.
CEO Jo Patterson said: “The introduction of the product through prescription channels will provide us with valuable feedback as we continue our clinical trial and endeavour to launch Bod Bio-Absorb 100 through the Australian pharmacy market in the coming months.”
Australian Natural Therapeutics Group
Australian Natural Therapeutics Group (ANTG) has launched a new medicinal cannabis oil grown and produced at its facility near Armidale, NSW.
Rocky Oil is a 30:1 THC to CBD mix for people suffering from conditions including chronic pain and insomnia.
Producer Northern Green Canada (NGC) has this week begun shipping its Shishkaberry cultivar to New Zealand firm Medleaf Therapeutics for immediate availability.
The flower product will be available from all major pharmacy wholesalers under the country’s new medicinal cannabis scheme.
NGC previously exported flower to New Zealand under the old regulatory regime, with an initial trial supply on a compassionate basis for several patients.
Medleaf director Courtney Letica said pricing is competitive with the illicit market, “delivering the next step on the path to affordability for Kiwi patients”.
The company has indicated interest in several cultivars from NGC to be commercialised later this year.